Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats benign prostatic hyperplasia (BPH). ANDA 210687, held by Msn. Silodosin.
As of Nov 14, 2026, ANDA 210687 (Silodosin), held by Msn, was first approved by FDA on Dec 3, 2018, with 1 approved supplement and 0 published complete response letters.
First approved: Dec 3, 2018
Review: Standard
Supplements approved: 1
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Silodosin capsule, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Silodosin capsule is not indicated for the treatment of hypertension.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
